289 related articles for article (PubMed ID: 32576578)
1. Identification of MicroRNAs With
Weidle UH; Nopora A
Cancer Genomics Proteomics; 2020; 17(4):321-334. PubMed ID: 32576578
[TBL] [Abstract][Full Text] [Related]
2. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748
[TBL] [Abstract][Full Text] [Related]
3. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
4. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
[TBL] [Abstract][Full Text] [Related]
5. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.
Alagpulinsa DA; Yaccoby S; Ayyadevara S; Shmookler Reis RJ
Cancer Biol Ther; 2015; 16(6):976-86. PubMed ID: 25996477
[TBL] [Abstract][Full Text] [Related]
6. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
[TBL] [Abstract][Full Text] [Related]
8. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
[TBL] [Abstract][Full Text] [Related]
9. miR-125a suppresses malignancy of multiple myeloma by reducing the deubiquitinase USP5.
Wu L; Zhang C; Chu M; Fan Y; Wei L; Li Z; Yao Y; Zhuang W
J Cell Biochem; 2020 Jan; 121(1):642-650. PubMed ID: 31452281
[TBL] [Abstract][Full Text] [Related]
10. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
11. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
[No Abstract] [Full Text] [Related]
12. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
13. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
14. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
16. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.
Zhao JJ; Lin J; Zhu D; Wang X; Brooks D; Chen M; Chu ZB; Takada K; Ciccarelli B; Admin S; Tao J; Tai YT; Treon S; Pinkus G; Kuo WP; Hideshima T; Bouxsein M; Munshi N; Anderson K; Carrasco R
Cancer Res; 2014 Mar; 74(6):1801-13. PubMed ID: 24599134
[TBL] [Abstract][Full Text] [Related]
17. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Leone E; Morelli E; Di Martino MT; Amodio N; Foresta U; Gullà A; Rossi M; Neri A; Giordano A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2013 Apr; 19(8):2096-106. PubMed ID: 23446999
[TBL] [Abstract][Full Text] [Related]
18. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
19. M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models.
Sanderson MP; Friese-Hamim M; Walter-Bausch G; Busch M; Gaus S; Musil D; Rohdich F; Zanelli U; Downey-Kopyscinski SL; Mitsiades CS; Schadt O; Klein M; Esdar C
Mol Cancer Ther; 2021 Aug; 20(8):1378-1387. PubMed ID: 34045234
[TBL] [Abstract][Full Text] [Related]
20. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
